Subscribe To Our Free Newsletter |
Glenmark Pharma spurts 2%; settles litigation with Forest Laboratories
The pharma company has entered into a Settlement Agreement with Forest Laboratories Forest Laboratories & Royalty Pharma Collection Trust to settle and dismiss the outstanding patent litigation related to Glenmark’s Abbreviated New Drug Application for Milnacipran Hydrochloride.